Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages
Methyllycaconitine
DOI:
10.1007/s00210-025-04225-5
Publication Date:
2025-05-31T10:02:39Z
AUTHORS (5)
ABSTRACT
Abstract Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is well-established for its metabolic benefits, including glycemic control and weight loss. Beyond these roles, it exhibits significant anti-inflammatory properties, though the mechanisms remain underexplored. This study investigates effects of liraglutide in lipopolysaccharide (LPS)-stimulated RAW 264.7 murine macrophages. Results demonstrate that increasing concentrations suppresses LPS-elevated prostaglandin E2 (PGE2), 6-keto F1α (6-keto-PGF 1α , stable prostacyclin metabolite) thromboxane A2 (TXA2), similar to observed with conventional agents, ibuprofen celecoxib. Mechanistic exploration reveals liraglutide's action dually-modulated by cyclooxygenase (COX) nicotinic acetylcholine (nAChR) signaling. The application non-selective, non-competitive nAChR antagonist or selective potent α7-nAChR antagonist, mecamylamine (MEC) methyllycaconitine (MLA), respectively, highlights involvement cholinergic pathways activity. Based on silico molecular docking analyses, favorable binding affinities COX-1, COX-2, synthase (PGIS), α7nAChRs, supporting potential multi-target effects. These findings suggest therapeutic may go beyond regulation be promising conditions which inflammatory converge, inflammation modulation
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (39)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....